医学
腹膜间皮瘤
间皮瘤
恶性肿瘤
腹膜
肿瘤科
病理
普通外科
内科学
作者
Shigeki Kusamura,Vahan Képénékian,Laurent Villeneuve,Robin J. Lurvink,Kim Govaerts,Ignace H. J. T. de Hingh,Brendan Moran,Kurt Van der Speeten,Marcello Deraco,Olivier Gléhen,Pedro Barrios-Sánchez,Joel Baumgartner,Almog Ben‐Yaacov,Rossella Bertulli,Peter Cashin,Tom Cecil,Sanjeev Dayal,Michele De Simone,Jason M. Foster,Diane Goèré
出处
期刊:Ejso
[Elsevier BV]
日期:2020-03-12
卷期号:47 (1): 36-59
被引量:113
标识
DOI:10.1016/j.ejso.2020.02.011
摘要
Peritoneal mesothelioma (PM) is a rare and aggressive primary peritoneal malignancy characterized by widespread multiple metastatic tumour nodules originating from the peritoneum. The conventional classification distinguishes diffuse malignant peritoneal mesothelioma (DMPM) and border-line forms: multicystic peritoneal mesothelioma (MCPM) and well-differentiated papillary peritoneal mesothelioma (WDPPM). Despite the novel achievements in the management of PM, there is difficulty in conducting randomized trials due to its rarity and aggressive biology in many cases. As there is, a necessity to standardize diagnosis and management of PM, the Peritoneal Surface Oncology Group International (PSOGI) commissioned a steering committee to elaborate clinical guidelines.
科研通智能强力驱动
Strongly Powered by AbleSci AI